OvCaPreMed · OvCa for Precision Medicine: Personalized Ovarian Cancer Treatment using High-Throughput and Microfluidic Drug Screening.
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2021-03-22 → 2024-03-21
- Финансиране от ЕС
- 200 992 €
- Участници
- 2
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Лекарства и комбинации от тях се тестват върху клетъчни проби от пациенти с рак на яйчниците чрез микрофлуидни технологии. Това помага за откриването на подходяща терапия за хора, при които стандартната химиотерапия с платина вече не действа.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
OvCa for Precision Medicine: Personalized Ovarian Cancer Treatment using High-Throughput and Microfluidic Drug Screening. The main issue with current Ovarian Cancer (OvCa) treatments is the eventual resistance to standard platinum-based chemotherapy, which ultimately leads patients to relapse. Identifying drugs and drug combinations that overcome platinum resistance by new treatment strategies is an unmet medical need in OvCa patients that I plan to address with our technology pipeline as a Proof-of-Concept. I, Deepak Balaji Thimiri Govinda Raj, under the supervision and mentorship of Dr. Dalu Mancama (Precision Medicine) and Dr. Janine Scholefield (Synthetic Biology) at CSIR South Africa along with Prof. Nicholas Dunne and Dr. David Kinahan at Dublin City University (DCU), propose developing a cutting-edge technology pipeline with which I will identify and screen drugs and drug combinations for relapsed OvCa patients who have exhausted all other treatment options. I will use OvCa patient samples to validate the drug screening pipeline as a Proof-of-Concept. Our technology pipeline includes strategies where I will combine tissue engineering (Prof. Nicholas Dunne’s team) with microfluidic technology (Dr. David Kinahan, DCU), Chemstress platform (Dr. Jerry Clifford, ValitaCell) and my expertise in chemical biology accumulated during my PhD and three post-doctoral placements. Using this pipeline, we aim to identify drug combinations that can overcome platinum resistance and ultimately provide tailored-specific therapy options for OvCa patients. We intend our technologies to provide clinically relevant drug combinations information to oncologists.
Оригинален текст от CORDIS (на английски).
Участници
- DUBLIN CITY UNIVERSITY · DublinКоординаторИрландия
- COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH · PretoriaЮжна Африка
Връзки
Данни: CORDIS, © Европейски съюз